Integrated Wealth Concepts LLC Buys 3,962 Shares of Kenvue Inc. (NYSE:KVUE)

Integrated Wealth Concepts LLC grew its position in Kenvue Inc. (NYSE:KVUE) by 12.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 35,022 shares of the company’s stock after purchasing an additional 3,962 shares during the quarter. Integrated Wealth Concepts LLC’s holdings in Kenvue were worth $810,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of KVUE. Riverview Trust Co acquired a new stake in Kenvue in the 3rd quarter valued at approximately $30,000. Ashton Thomas Securities LLC bought a new stake in shares of Kenvue in the third quarter valued at approximately $35,000. Studio Investment Management LLC grew its stake in shares of Kenvue by 52.1% in the second quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock worth $45,000 after acquiring an additional 845 shares during the last quarter. Deseret Mutual Benefit Administrators increased its position in Kenvue by 49.7% during the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock worth $45,000 after acquiring an additional 651 shares during the period. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new position in Kenvue during the 2nd quarter valued at $61,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have issued reports on KVUE. Jefferies Financial Group began coverage on shares of Kenvue in a research report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price target on the stock. Royal Bank of Canada downgraded Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 target price on the stock. in a research report on Tuesday, September 24th. JPMorgan Chase & Co. upped their price target on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Bank of America lifted their price objective on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. Finally, Piper Sandler upped their target price on Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research note on Monday, September 23rd. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and a consensus target price of $22.64.

Kenvue Stock Performance

Kenvue stock opened at $22.81 on Tuesday. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The stock has a fifty day moving average price of $22.96 and a two-hundred day moving average price of $21.13. The firm has a market capitalization of $43.73 billion, a P/E ratio of 41.47, a P/E/G ratio of 2.07 and a beta of 1.37.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The business had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The firm’s revenue for the quarter was down .4% on a year-over-year basis. During the same quarter last year, the company posted $0.31 EPS. As a group, analysts anticipate that Kenvue Inc. will post 1.07 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th were issued a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.59%. The ex-dividend date was Wednesday, November 13th. Kenvue’s payout ratio is currently 149.09%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.